Theriva Biologics, Inc. (TOVX), Monday, announced positive results from the second Independent Data Monitoring Committee or IDMC review of its VIRAGE Phase 2b clinical trial.
The IDMC concluded that VCN-01, when combined with the standard chemotherapy or gemcitabine/nab-paclitaxel, was well tolerated by patients with metastatic pancreatic ductal adenocarcinoma or PDAC.
The adverse event profile was consistent with expectations for both the patient population and the treatments being tested.
The VIRAGE trial has completed patient enrollment, with 101 patients enrolled across five U.S. sites and nine sites in Spain.
Topline clinical data from the study is expected in Q2 2025.
If the results are positive, they will inform the design of a potential Phase 3 trial for regulatory approval.
Theriva Biologics remains focused on advancing its novel oncolytic adenovirus platform, with a goal of providing new cancer treatment options, including VCN-01, for metastatic PDAC and other cancers.
Currently, TOVX is trading at $1.11 down by 1.91 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.